TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07321574: An Open-Label, Multi-Cohort Phase IIb Clinical Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors

Sponsor: Shanghai AB PharmaTech Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 110 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,873,400

Rescue Site Savings

+$7,854,000

Unlock Full NCT07321574 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07321574 Rescue Dossier →